Metromicon-Neo, vaginal suppositories 500 mg+100 mg 14 pcs

Metromicon-Neo is a combined drug with antiprotozoal, antifungal and antibacterial action.

Metronidazole is active against Gardnerella vaginalis; protozoa: Trichomonas vaginalis, Giardia intestinalis, Entamoeba histolytica; anaerobic gram-negative bacteria: Bacteroides spp. (B. fragilis, B. diestasoinis, B. ovatus, B. thetaiotaomicron, B.vulgatus), Fusobacterium spp, Prevotella spp. (P. bivia, P. buccae, P.disiens); anaerobic gram-positive bacteria: Clostridium spp., Eubacterium spp.; anaerobic gram-positive cocci: Peptococcus spp., Peptostreptococcus spp. Aerobic microorganisms and facultative anaerobes are resistant to metronidazole. The mechanism of action is due to the biochemical reduction of the 5-nitrogroup of metronidazole by intracellular transport proteins of anaerobic microorganisms and protozoa. The reduced 5-nitrogroup of metronidazole interacts with the DNA of the microbial cell, inhibiting the synthesis of their nucleic acids, which leads to the death of the bacteria.

The most sensitive to miconazole are dermatomycetes and yeasts. It is active against the causative agent of variegated lichen (Malassezia furfur), causative agents of some dermatomycoses (Candida albicans, Trichophyton, Epidermophyton floccosum, Microsporum).It shows activity against Dimorphons fungi, Cryptococcus neoformans, Aspergillus spp, Pityrosporum, Torulopsis glabrata, Pseudallescheria boydii; some gram-positive microorganisms, including staphylococci and streptococci. Fungicide and fungistatic effect of myconazole nitrate is due to inhibition of ergosterol biosynthesis of the shell and plasma membranes of fungi, changes in lipid composition and cell wall permeability, causing cell death of fungus.

Indications

Vaginal infections:

Active ingredient

Composition

Active substances:

Miconazole nitrate – 100 mg,

metronidazole – 500 mg.

Excipients:

semisynthetic glycerides.

How to take, the dosage

Intravaginally.

Acute vaginitis, bacterial vaginosis: 1 suppository in the morning and at night for 7 consecutive days.

Chronic vaginitis: 1 suppository 1 time a day, just before bedtime, for 14 consecutive days.

Frequently recurrent vaginitis or in the absence of positive clinical dynamics with other treatments: 1 suppository in the morning and at night for 14 days.

Prelease the suppository from its wrapping with scissors (cut the film around the suppository) and insert it deep into the vagina.

Interaction

Due to penetration of metronidazole into the systemic blood flow the following interaction reactions may be observed when concomitant use with some substances:

Oral anticoagulants: the effect of indirect anticoagulants is increased.

Disulfiram: CNS disorders (psychiatric reactions) may be observed; metronidazole should not be administered to patients who have taken disulfiram in the last 2 weeks.

Phenytoin: The blood concentration of phenytoin is increased, and the blood concentration of metronidazole is decreased.

Lithium preparations: there may be an increase in their toxicity.

Phenobarbital: decreases the concentration of metronidazole in blood.

Cimetidine: Metronidazole blood concentrations may increase.

Astemizole and terfenadine: Metronidazole and miconazole inhibit the metabolism of these drugs and increase plasma concentrations.

Ethanol: interaction of metronidazole with ethanol causes disulfiram-like reactions.

Special Instructions

At the time of use of the drug, you should refrain from sexual intercourse. In order to avoid reinfection, concomitant treatment of the sexual partner is necessary. In case of trichomonas vaginitis, simultaneous treatment of the sexual partner with oral metrbnidazole is advisable.

At the time of treatment and for at least 24-48 hours after the end of treatment, ethanol should be avoided (ethanol intolerance is possible).

The simultaneous use of the drug with contraceptive diaphragms and rubber or latex condoms is not recommended (possible interaction with price suppositories).

In case of severe vaginal irritation, treatment with the drug should be discontinued.

The suppositories should only be used intravaginally and should not be swallowed or otherwise administered.

If the drug is used in conjunction with oral metronidazole, especially with repeated courses, peripheral blood counts should be monitored (danger of leukopenia).

Impact on the ability to drive vehicles and operate potentially dangerous mechanisms: Caution is recommended because possible, negative effects on the ability to drive and operate complex mechanisms cannot be excluded. In case of side effects from the central nervous system one should refrain from driving motor transport and operating potentially dangerous mechanisms.

Contraindications

With caution: with hepatic and renal insufficiency, porphyria, hematopoiesis and diseases of the peripheral and central nervous system, diabetes, microcirculatory disorders, pregnancy (II and III trimesters).

Side effects

Local reactions: burning, itching, irritation of the vaginal mucosa and increased swelling. Due to inflammation of the vaginal mucosa in vaginitis, irritation may increase after the first suppository has been inserted or by the third day of treatment. These complications quickly disappear after stopping treatment.

Gastrointestinal tract: abdominal pain or cramps, “metallic” taste, dry mouth, constipation, diarrhea, loss of appetite, nausea, vomiting.

Nervous system disorders: headache, motor disorders (ataxia), dizziness, psycho-emotional disorders, seizures.

Hematopoietic system disorders: leukopenia.

Allergic reactions: skin rashes, including urticaria.

Overdose

When following the recommended doses, due to the low absorption of the drug, no cases of overdose have been identified.

Possible symptoms: nausea, vomiting, abdominal pain, diarrhea, itching, metallic taste in the mouth, ataxia, dizziness, paresthesias, peripheral neuropathy (with long-term use in high doses), seizures, leukopenia, dark staining of urine (caused by metronidazole overdose).

The symptoms of myconazole overdose have not been identified.

Treatment: symptomatic and supportive therapy, gastric lavage in case of accidental ingestion.

Pregnancy use

Prescription of the drug is contraindicated in the first trimester of pregnancy. Administration in II and III trimesters of pregnancy is possible only if the potential benefit to the mother exceeds the possible risk to the fetus.

If it is necessary to prescribe the drug during lactation, breastfeeding should be stopped because metronidazole penetrates into the breast milk. Breastfeeding can be resumed 24-48 h after the end of treatment.

Similarities